$APMD SEC Filings

U.S. Food and Drug Administration (“FDA”) Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi™, and assigned a PDUFA target action date of February 28, 2027

Received 6,915,837 shares by conversion · Disposed of 6,915,837 shares (Other Transaction) · Acquired 6,915,837 shares (Other Transaction) · 1 more

Received 7,054,956 shares by conversion

Disposed of 333,580 Stock Option (Right to Buy) (Disposition to Issuer) · Granted 333,580 Stock Option (Right to Buy) · Granted 31,434 Stock Option (Right to Buy) · 2 more

Granted 108,916 Stock Option (Right to Buy) · Disposed of 1,369,322 Stock Option (Right to Buy) (Disposition to Issuer) · Granted 1,369,322 Stock Option (Right to Buy)

Granted 44,477 Stock Option (Right to Buy) · Disposed of 140,844 Stock Option (Right to Buy) (Disposition to Issuer) · Granted 140,844 Stock Option (Right to Buy)

Granted 44,477 Stock Option (Right to Buy) · Disposed of 140,844 Stock Option (Right to Buy) (Disposition to Issuer) · Granted 140,844 Stock Option (Right to Buy)

Granted 177,796 Stock Option (Right to Buy) · Bought 12,500 shares ($200K) · Disposed of 191,706 Stock Option (Right to Buy) (Disposition to Issuer) · 2 more

Granted 44,477 Stock Option (Right to Buy) · Acquired 44,477 Stock Option (Right to Buy) (Disposition to Issuer) · Granted 44,477 Stock Option (Right to Buy)

Returned 448,247 shares to the issuer · Received 448,247 shares as a grant or award · Received 10,845 shares by conversion · 2 more

Granted 55,596 Stock Option (Right to Buy) · Returned 58,014 shares to the issuer · Received 58,014 shares as a grant or award · 3 more